Jonathan Krinsky, chief market technician at BTIG, joins CNBC's 'The Exchange to discuss his outlook on stocks for 2025, what ...

BTIG lowered the firm’s price target on Staar Surgical (STAA) to $39 from $49 and keeps a Buy rating on the shares as part of a broader ...

BTIG analyst Ryan Zimmerman maintained a Buy rating on Staar Surgical (STAA – Research Report) today and set a price target of $39.00. The ...

Poseida Therapeutics Inc (PSTX) stock saw a decline, ending the day at $9.4 which represents a decrease of $-0.20 or -2.08% from the prior close of $9.6. The stock opened at $9.54 and touched a low of ...

BTIG raised the firm’s price target on Insulet (PODD) to $300 from $270 and keeps a Buy rating on the shares as part of a broader research note updating the firm’s models in select Medical Technology ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 13.40% ...

Jonathan Krinsky, BTIG chief market technician, joins 'Closing Bell' to discuss why he's cautious on Apple and the market ...

BTIG analyst Marie Thibault raised the firm’s price target on Boston Scientific (BSX) to $101 from $97 and keeps a Buy rating ...

Analyst initiates coverage on cloud-based auto services provider SunCar Technology (SDA) with Buy rating, projecting 25% annualized growth.

According to a BTIG strategist, the rally in the index was rejected from the previous support trendline and even though there are still four days left for the Santa Claus rally to deliver gains, there ...

On Monday, BTIG analyst adjusted the price target for Insulet (NASDAQ:PODD) Corporation (NASDAQ:PODD) stock, increasing it from $270.00 to $300.00, while reaffirming a Buy rating for the company.

On Monday, BTIG analyst adjusted the price target for Insulet (NASDAQ:PODD) Corporation (NASDAQ:PODD) stock, increasing it from $270.00 to $300.00, while reaffirming a Buy rating for the company. For ...